Adverts

Open Access Articles- Top Results for Ifoxetine

Ifoxetine

</th></tr>
Ifoxetine
File:Ifoxetine.png
Systematic (IUPAC) name
(3R,4S)-4-(2,3-dimethylphenoxy)piperidin-3-ol
Clinical data
  • Uncontrolled
Oral
Identifiers
66208-11-5
None
PubChem CID 71971
ChemSpider 64977
UNII LHH887104B 7pxY
Chemical data
Formula C13H19NO2
221.30 g/mol

Ifoxetine (CGP-15,210-G) is a selective serotonin reuptake inhibitor (SSRI) which was investigated as an antidepressant in the 1980s but was never marketed.[1][2][3] Ifoxetine selectively blocks the reuptake of serotonin in the brain supposedly without affecting it in the periphery.[3] Supporting this claim, ifoxetine was found to be efficacious in clinical trials and was very well tolerated, producing almost no physical side effects or other complaints of significant concern.[3]

References

  1. Burrows GD, McIntyre IM, Judd FK, Norman TR (August 1988). "Clinical effects of serotonin reuptake inhibitors in the treatment of depressive illness". The Journal of Clinical Psychiatry. 49 Suppl: 18–22. PMID 3045107. 
  2. Waldmeier PC, Maître L, Baumann PA et al. (October 1986). "Ifoxetine, a compound with atypical effects on serotonin uptake". European Journal of Pharmacology 130 (1-2): 1–10. PMID 2877890. doi:10.1016/0014-2999(86)90177-9. 
  3. 3.0 3.1 3.2 Delini-Stula A, Fischbach R, Gauthier JM et al. (July 1987). "First clinical experience with ifoxetine, a new 5-HT reuptake blocker with particular emphasis on the side-effect profile of the 5-HT-uptake inhibiting drugs". International Clinical Psychopharmacology 2 (3): 201–15. PMID 3320185. doi:10.1097/00004850-198707000-00003. 



Lua error in package.lua at line 80: module 'Module:Buffer' not found.